cEVR

Related by string. * * *

Related by context. All words. (Click for frequent words.) 79 complete Early Virological 72 undetectable hepatitis C 71 SVR# 70 Virologic 69 PEG IFN 68 pegylated interferon alpha 68 Response Evaluation Criteria 68 DAS# CRP 68 CCyR 68 PegIFN RBV 68 CIMZIA TM 68 achieved CCyR 68 Rate ORR 68 log# reduction 68 IU ml 68 HBeAg seroconversion 67 ertapenem 67 microbiological eradication 67 CR nPR 67 achieved sustained virologic 67 TMC# r 67 HBeAg positive patients 67 Rapid Virological Response 67 log# copies mL 67 Crohn Disease Activity 67 ACTEMRA TM 66 relapsed MM 66 lopinavir r arm 66 bortezomib refractory 66 undetectable HCV RNA 66 8mg/kg 66 Partial Response 66 RECIST Response Evaluation Criteria 66 Index CDAI 66 sustained virologic response 66 Median PFS 66 sustained virological response 66 ribavirin RBV 66 PEG Interferon alfa 66 MCyR 66 antibody titer 66 BARACLUDE ® 66 virologic response EVR 66 tipranavir ritonavir 66 biochemical relapse 65 mg TID 65 oxycodone CR 65 R# #mg BID 65 IFN α 65 EBMT criteria 65 ug kg 65 achieved ACR# 65 SPRYCEL ® 65 CIMZIA ™ 65 dose cohort 65 CIMZIA TM certolizumab pegol 65 ARCALYST ® 65 Solid Tumors criteria 65 detectable HCV RNA 65 Hycamtin ® 65 HBeAg 65 FluCAM arm 65 evaluable subjects 65 Peginterferon Alfa 2a 65 -#.# log# 65 ACR# ACR# 65 serum HBV DNA 65 ug dose 65 invasive aspergillosis 65 rapid virologic response 65 highly emetogenic 65 Rapid Virologic Response 65 alfa 2a 64 morphometric vertebral fractures 64 undetectable HBV DNA 64 tipranavir r 64 Engerix B 64 CRp 64 FOLFOX6 64 Timed Walk 64 ara C 64 progression TTP 64 virologic response 64 CDAI 64 Pharmacokinetic parameters 64 response CCyR 64 Peg IFN 64 Achieves Primary Endpoint 64 adalimumab Humira 64 ribavirin therapy 64 complete cytogenetic 64 HBeAg negative patients 64 Lymphocytic 64 endoscopic remission 64 plus dexamethasone 64 peg interferon 64 Flu Cy 64 GOUT 64 HPV-#/# 64 Aptivus ® 64 REYATAZ r 64 peginterferon alfa 64 Secondary endpoints include 64 mg/m2 dose 64 confirmed CCyR 64 Dose Escalation 63 recurrent genital herpes 63 HBsAg 63 cytogenetic response 63 Pegasys plus Copegus 63 XIENCE V PROMUS Stent 63 MAGE A3 ASCI 63 HCV Genotype 63 Folfox 63 antiretroviral naïve 63 Treated Patients 63 elevated ALT 63 treatment naive genotype 63 RECIST criteria 63 chlorambucil 63 peginterferon alfa 2a #KD 63 hemagglutination inhibition HAI 63 mg BID dose 63 partial remissions 63 Peginterferon 63 Non inferiority 63 annualized relapse 63 recurrent glioblastoma multiforme 63 peginterferon alfa 2a 63 mRCC 63 Virological 63 mcg BID 63 q#h 63 ACR# response 63 ritonavir boosted 63 APTIVUS r 63 hemagglutination inhibition 63 HCV RESPOND 2 63 ACR Pedi 63 HIV RNA 63 Antiviral Activity 63 Valopicitabine 63 Chronic Hepatitis C 63 Copegus ribavirin 63 mg qd 63 undetectable virus HCV 63 PegIFN 63 Adjuvant Treatment 63 CDAI score 63 mcg albinterferon alfa 2b 63 Hormone Refractory Prostate Cancer 63 Free Survival PFS 63 Omacetaxine 63 plus ribavirin 63 IU mL 63 Oral Fingolimod 63 Randomized Phase 63 % Confidence Interval 63 undetectable viral 63 % CI #.#-#.# [003] 63 clinically evaluable patients 63 #mg BID [002] 63 DAS# remission 63 Pegasys peginterferon alfa 2a 63 virologic failure 63 VELCADE melphalan 63 certolizumab 63 achieved sustained virological 63 treatment naïve genotype 62 Platinol ® 62 Kaplan Meier estimates 62 Aloxi injection 62 CR CRu 62 virological response 62 mcg QD 62 NMIBC 62 peginterferon 62 viral kinetics 62 complete cytogenetic response 62 #.#mg/dL 62 posaconazole 62 Phase 2b Clinical Trial 62 serum urate 62 REYATAZ r arm 62 oral FTY# 62 Placebo Controlled Trial 62 calculated creatinine clearance 62 nodular partial response 62 Prolongs Survival 62 PASI scores 62 5 Fluorouracil 62 Pegasys ® 62 CIN2 + 62 HCV SPRINT 62 naïve HCV 62 unfractionated heparin UFH 62 atazanavir ritonavir 62 p = NS 62 Doxil ® 62 -#.# log# copies mL 62 receiving INTRON 62 #mg QD [002] 62 Follicular Lymphoma 62 seroprotection 62 serum antibody 62 ritonavir boosted atazanavir 62 ACR# responses 62 Sustained virologic response 62 heFH 62 severe neutropenia 62 HBV DNA levels 62 PEGylated Fab fragment 62 plus prednisone 62 dasatinib Sprycel ® 62 doripenem 62 non nucleoside inhibitor 62 q8h 62 mg kg dose 62 TPV r 62 liposome injection 62 mg QD 62 virologic failures 62 proctitis 62 relapsed MCL 62 Aflibercept 62 ALT elevation 62 rapid virological response 62 evaluating tivozanib 62 log# IU mL 62 aspartate aminotransferase 62 Operative mortality 62 FluCAM 62 #mg BID [001] 62 pegylated interferon alfa 2a 62 piperacillin tazobactam 62 RGT arm 62 Hepatotoxicity 62 mg/m2/day 62 estramustine 61 gemcitabine cisplatin 61 Trial Evaluating 61 Solid Tumors RECIST 61 telaprevir pegylated interferon 61 serologically active patients 61 K ras mutations 61 experienced virologic failure 61 Natalizumab 61 Phase Ib Clinical Trial 61 μg dose 61 MERIT ES 61 metastatic CRC 61 Tipranavir 61 Replikin Count 61 Infected Patients 61 remission CR 61 ALT normalization 61 lymphocytosis 61 comparator arm 61 TLUS 61 reactogenicity 61 CTAP# Capsules 61 novel VDA molecule 61 dosing cohorts 61 Hepatitis B Virus 61 Naive Patients 61 LymphoStat B belimumab 61 metastatic malignant 61 secondary efficacy endpoint 61 interferon ribavirin 61 Interferon Beta 61 HBV DNA 61 HBeAg positive 61 ARCOXIA 61 log# 61 PREZISTA ritonavir 61 FOLFIRI 61 Secondary endpoints included 61 Severity Index PASI 61 mg ustekinumab 61 hypophosphatemia 61 Gastrointestinal Stromal Tumors 61 hepatitis C genotype 61 mcg mL 61 FOLPI 61 antiviral efficacy 61 bacillus Calmette Guerin 61 Bezielle 61 pegylated alpha interferon 61 interferon γ 61 HCV RNA 61 pegylated interferon alfa 61 Capacity FVC 61 PEG interferon 61 resected pancreatic cancer 61 biologic DMARD 61 KRAS mutations occur 61 CLL SLL 61 4mg/kg 61 oblimersen 61 interferon alfa 61 plasma HCV RNA 61 enterococcal 61 low dose cytarabine 61 plus prednisone prednisolone 61 fosamprenavir 61 HBeAg negative 61 Phase 2b Study 61 Pooled Analysis 61 serum aminotransferase levels 61 Meets Primary Endpoint 61 EGFR TKI 61 HIV coinfected 61 HBeAg + 61 Treatment Naive Patients 61 metastatic renal cell 61 Advanced Melanoma 61 serum HCV RNA 61 Combination REOLYSIN R 61 combination antiretroviral therapy 61 cisplatin gemcitabine 61 budesonide foam 61 elotuzumab 61 antiretroviral naive 61 prospectively defined 61 moderately emetogenic 61 rFSH 61 #mg dose [002] 61 leukocyte count 61 peginterferon alpha 2a 61 ORENCIA ® 61 LEXIVA r 61 Relapsing Remitting Multiple Sclerosis 61 Solid Tumors 61 serum phosphorous 61 follicular lymphomas 61 atazanavir sulfate 61 Decitabine 61 Desvenlafaxine Succinate 61 Psoriasis Area 61 dosing cohort 61 binary restenosis 61 VFEND 61 Metastatic Renal Cell Carcinoma 61 virus HCV protease inhibitor 61 Traficet EN 61 Platelet counts 61 Pharmacokinetics PK 61 doxorubicin cyclophosphamide 61 Lupuzor ™ 61 Study Evaluating 61 aspartate aminotransferase AST 61 Telbivudine 61 achieved PASI 61 lumbar spine BMD 61 alanine aminotransferase ALT 61 null responders 60 Patients Receiving 60 hematological parameters 60 pT3 60 q#d 60 3mg/kg 60 Fulvestrant 60 selective modulator 60 Respiratory Syncytial Virus 60 CAELYX 60 efalizumab 60 achieve sustained virologic 60 COMBIVIR 60 prednisone prednisolone plus 60 crizotinib PF # 60 Lenalidomide 60 decitabine 60 Single Dose 60 Nilotinib 60 receiving VICTRELIS 60 seroconverted 60 Scale EDSS 60 demonstrated antitumor activity 60 Improves Outcomes 60 serum prostate 60 echocardiographic parameters 60 RAPTIVA 60 MIC# [001] 60 S. aureus isolates 60 Antitumor Activity 60 Mg Usa 60 oral Hycamtin 60 Primary endpoints 60 pCR 60 alpha 2a 60 Septic Shock 60 Pegylated Interferon 60 evaluable 60 pegylated interferon alfa 2b 60 Tumor Response 60 standard chemotherapy regimen 60 PREZISTA r arm 60 cisplatin vinorelbine 60 IL#B 60 neurologic progression 60 efavirenz EFV 60 patients coinfected 60 albumin excretion rate 60 patients evaluable 60 pegylated interferon 60 Known hypersensitivity 60 DLTs 60 #mg/m# [001] 60 Adefovir 60 mg m² 60 Histologic 60 oral rivaroxaban 60 ritonavir boosted lopinavir 60 nucleotide analog 60 Ranolazine 60 fluvastatin 60 leukemia AML 60 invasive candidiasis 60 refractory AML 60 cells uL 60 Dasatinib 60 virologic 60 Xeloda ® 60 dexamethasone Decadron 60 mcg dose 60 elevated transaminases 60 octreotide LAR 60 DOXIL 60 low expressors 60 statistical significance p 60 Pivotal Phase 60 Phase IIb Clinical Trial 60 Bosutinib 60 Nebulized 60 epoetin alpha 60 irinotecan cisplatin 60 ABC/3TC 60 Acute Ischemic Stroke 60 Non Responders 60 IRLS score 60 Cimzia TM 60 mycophenolate mofetil 60 IELT 60 Demonstrates Sustained 60 Infusion Reactions Severe 60 APTIVUS 60 YERVOY 60 Shows Efficacy 60 COPEGUS 60 Pharmacodynamic 60 pegIFN 60 Adalimumab 60 sipuleucel T 60 #mg q8h 60 antibody MAb 60 monoinfected patients 60 cytogenetic responses 60 Phase IIb Trial 60 Cholinesterase Inhibitors 60 genotypic resistance 60 p# antigen 60 median survivals 60 abacavir lamivudine 60 CCX# B 60 ALT elevations 60 microgram kg 60 telaprevir dosed 60 cells mcL 60 RECORD1 60 antibody titers 60 See WARNINGS 60 mg RDEA# 60 BARACLUDE R 60 FUSILEV enhances 60 Mg Uk 60 hematologic toxicity 60 CANCIDAS 60 pT2 60 Moxifloxacin 60 Bacteremia 60 plus gemcitabine 60 FROVA 60 Relapsing Multiple Sclerosis 60 See CLINICAL PHARMACOLOGY 60 metastatic GIST 60 clodronate 60 neutropenia dehydration dyspnea 60 sUA 60 virologically suppressed 60 placebo dexamethasone 60 MKC# MT 60 PSA nadir 59 INCB# [003] 59 Randomized Clinical Trials 59 orally administered inhibitor 59 Cystatin C 59 amprenavir 59 inhibitor RG# 59 Betaferon R 59 postdose 59 Partial Responses 59 CD8 responses 59 administered subcutaneously 59 azilsartan medoxomil 59 Novel Oral 59 receiving golimumab 59 CK # plasma concentrations 59 PEGylated anti 59 CIN3 59 atazanavir Reyataz 59 protease inhibitor PI 59 mg tid 59 Severe Sepsis 59 tumor progression TTP 59 oral ridaforolimus 59 median PFS 59 humanized interleukin 6 59 null responder 59 Degarelix 59 postintervention 59 virologic suppression 59 Cethromycin 59 K#N 59 urinary N telopeptide 59 nadolol 59 neutropaenia 59 bronchial hyperresponsiveness 59 generalized edema 59 pegylated interferon alpha 2a 59 Sustained Virologic Response 59 Fungal Infections 59 aminotransferase elevations greater 59 HCV genotype 59 Raptiva r 59 HES CEL 59 corticosteroid dose 59 Tyrosine Kinase Inhibitor 59 TO AVOID PREGNANCY WHILE 59 low dose ritonavir 59 mg BID 59 HI titers 59 Relapsed Multiple Myeloma 59 mg XP# 59 amoxicillin clavulanate 59 ASCO abstract 59 PEGINTRON TM 59 ZOLINZA 59 MADRS score 59 undetectable viral load 59 genotype 1b 59 Allogeneic 59 Viread Emtriva 59 fluconazole resistant 59 angiographic outcomes 59 cells μL 59 INCB# [001] 59 Vaccine Adjuvant 59 GW# [003] 59 mitoxantrone plus 59 Double Blind Randomized 59 Ishak fibrosis score 59 refractory NSCLC 59 TEAEs 59 dacarbazine DTIC 59 Demonstrated Significant 59 rizatriptan 59 free survival PFS 59 Anti Tumor Activity 59 Virologic failure 59 clinicopathological features 59 Castration Resistant Prostate Cancer 59 oral diclofenac 59 desvenlafaxine succinate 59 evaluable patients 59 Teriflunomide 59 splenectomized patients 59 abnormal p# biomarker 59 MGd 59 peripheral sensory neuropathy 59 lopinavir r 59 STRIDE PD 59 CYP#A# CYP#D# 59 Treatment Experienced 59 #mg/day [002] 59 Viral load 59 Phase 2a Trial 59 NRTI resistance 59 malignancy HCM 59 noninferior 59 Metastatic Prostate Cancer 59 Myelosuppression 59 Interferon alfa 59 cervical intraepithelial neoplasia 59 Pralatrexate 59 pegylated IFN 59 HAMD 59 Elitek 59 Glufosfamide 59 Vicriviroc 59 CCR5 tropic 59 HCV viral 59 Hsp# Inhibitor 59 doxorubicin docetaxel 59 interferon gamma 1b 59 somatostatin analog 59 ® emtricitabine 59 mL/min/#.# m 2 59 sunitinib Sutent ® 59 Forodesine HCl 59 Fludara 59 Median progression 59 adjuvant GIST 59 Is Well Tolerated 59 ischemia driven 59 beta 1a 59 GSK# [001] 59 Stent Restenosis 59 haematologic 59 HER2 overexpression 59 virologic responses 59 anemia hemoglobin 59 PROSTVAC VF 59 IgG antibody 59 replicon 59 nucleoside naive patients 59 mutated KRAS 59 QTc prolongation 59 TNF Tumor Necrosis Factor 59 Placebo Controlled Study 59 STELARA ® 59 trastuzumab Herceptin R 59 pyrexia mucositis sepsis febrile 59 PEGylated interferon beta 1a 59 #mg BID [003] 59 macroalbuminuria 59 adefovir dipivoxil 59 Complete Remission 59 LPV r 59 RNA copies mL 59 Fidaxomicin 59 specific antigen PSA 59 HCV genotype 1 59 Renal Cell Carcinoma 59 iPTH 59 Kinoid 59 Retreatment 59 transaminases 59 Main Outcome Measure 59 Montgomery Asberg Depression 59 Nesiritide 59 reduce serum phosphate 59 seropositivity 59 mcg kg 59 icatibant 59 lymphopenia 59 unstable angina pectoris 59 Disease Progression 59 viral titers 59 mg p = 59 AST ALT 59 FOLFOX4 59 Arch Intern Med 59 pmol L 59 gemcitabine carboplatin 59 Hypotension 59 pretreatment serum 59 AZT zidovudine Retrovir 59 Amrubicin 59 Non Alcoholic Steatohepatitis 59 CYT# potent vascular disrupting 59 baseline FEV 59 Haptoglobin 59 Pivotal Phase III 59 pimecrolimus cream 59 Efficacy Trial 59 co receptor tropism 59 Neoadjuvant 59 Demonstrates Statistically Significant 59 μg doses 59 fatigue asthenia 59 QTcF 59 metastatic castration resistant 59 peg IFN 59 CMV disease 59 anthracycline taxane 59 chronic HCV genotype 59 pooled comparator 59 boosted protease inhibitor 59 Monotherapy 59 vidofludimus 59 recurrent GBM 59 RECIST 59 glycated hemoglobin levels 59 Thal Dex 59 achieved undetectable HCV 59 definite stent thrombosis 59 APTIVUS R 59 #μg [001] 59 Cancer Incidence Mortality 59 HER2 expression 59 mucosal healing 59 oral allopurinol 58 cancer mCRC 58 Treatment Naïve 58 baseline HbA1c 58 Expanded Disability Status 58 liposomal amphotericin B 58 REYATAZ ® 58 CLARITY study 58 activated partial thromboplastin 58 clinically meaningful improvement 58 stage IIIb IV 58 Demonstrates Positive 58 Darunavir 58 caspofungin 58 tigecycline 58 TRANSFORMS 58 CHAMPION PCI 58 ST Elevation Myocardial 58 PSMA ADC 58 mitoxantrone chemotherapy 58 Improved Survival 58 mapatumumab 58 Xanafide 58 TIMP 1 58 antithymocyte globulin 58 locoregional recurrence 58 Multiple Myeloma MM 58 coinfected 58 #mg dosing group 58 p# biomarker 58 uM 58 Parathyroid Hormone 58 REMICADE monotherapy 58 ng dL 58 transaminase 58 heavily pretreated 58 TAXUS p value 58 R adefovir dipivoxil 58 Telintra 58 SCIg 58 neutropenia febrile neutropenia 58 adenoma recurrence 58 timepoint 58 TMC# C# 58 grade cervical intraepithelial 58 Inhaled Nitric Oxide 58 imipenem 58 IMPACT DCM 58 CCR5 tropic HIV 58 5-FU/LV 58 TNF antagonists 58 salmeterol fluticasone propionate 58 NATRECOR R 58 Epratuzumab 58 Initiate Phase 58 preintervention 58 Clostridium difficile Infection 58 darunavir r 58 Telaprevir VX 58 pharmacokinetic PK profile 58 Febrile neutropenia 58 Velcade bortezomib 58 Omiganan 58 Paraplatin ® 58 Tesmilifene 58 achieve sustained virological 58 paclitaxel cisplatin 58 balsalazide 58 Secondary endpoints 58 Refractory Hodgkin Lymphoma 58 elacytarabine 58 neutrophil count 58 Sandostatin R 58 μmol L 58 biochemical recurrence 58 Leukemias 58 colorectal carcinoma 58 μg kg 58 nadroparin 58 external genital lesions 58 HCV Protease Inhibitor 58 e antigen HBeAg 58 Stage IIB 58 complement inhibitor eculizumab 58 Xelox 58 F FDG PET 58 HCV genotypes 58 HLA DR2 58 solithromycin 58 concentration Cmax 58 Albuferon TM 58 FOLFOX4 alone 58 mcg linaclotide 58 tenofovir emtricitabine 58 Viral Load 58 CYP#A# substrate 58 FOLFOX regimen 58 fludarabine cyclophosphamide 58 PreCISe study 58 iniparib BSI 58 Aurora Kinase 58 Demonstrate Significant 58 Randomized Evaluation 58 nucleoside naive 58 glycosylated hemoglobin HbA1c 58 mITT population 58 Pemetrexed 58 CRMD# 58 Peginterferon alfa 2b 58 Amplicor 58 imatinib therapy 58 BRIM3 58 Hormone Receptor Positive 58 non splenectomized 58 plus aztreonam 58 Ribavirin causes 58 forodesine 58 Pegylated interferon 58 TAXUS Stent 58 adjunctive placebo 58 ® fluocinonide Cream 58 myelodysplastic myeloproliferative diseases 58 ULORIC 58 Tezampanel 58 mU liter 58 â ‰ ¥ 58 dacarbazine 58 chills fever headache 58 del 5q MDS 58 Linezolid 58 seroconversion 58 fosbretabulin 58 lamivudine refractory patients 58 Subtype 58 Nosocomial 58 adefovir 58 Ophena TM 58 Plaque Psoriasis 58 Cmax 58 Acetate Rectal Suppositories 58 refractory chronic lymphocytic 58 Preclinical Study 58 plasma uric acid 58 NIH CPSI 58 Randomized Double blind 58 cyclophosphamide methotrexate 58 Streptococcus pyogenes 58 lymphocyte count 58 PANVAC VF 58 Immunomedics Announces 58 plus methotrexate 58 teriflunomide 58 Catheter Associated 58 Target Lesion Revascularization TLR 58 TYGACIL 58 alanine aminotransferase 58 lispro 58 events MACE 58 mCi kg 58 Brentuximab Vedotin SGN 58 BENCHMRK 58 NNRTI resistance 58 Hemodialysis Patients 58 Phase Ib study 58 ELACYT 58 postvaccination 58 abdominal pain abdominal discomfort 58 prospectively stratified 58 ARB telmisartan 58 severe oral mucositis 58 HDRS 58 Pharmacokinetic Study 58 LANTUS ® 58 % CI #.#-#.# [005] 58 FOLFIRI alone 58 achieving PASI 58 underwent surgical resection 58 Newly Diagnosed Multiple Myeloma 58 receiving prophylactic anticoagulation 58 vincristine doxorubicin 58 Idiopathic Pulmonary Fibrosis 58 lumiliximab 58 metastatic hormone refractory 58 Demonstrates Efficacy 58 Vitro Activity 58 virologically 58 tumor lysis syndrome 58 Phase #/#a trial 58 entecavir 58 dasatinib Sprycel 58 posttreatment 58 tolterodine ER 58 Hb A1C 58 CCX# 58 adult chronic ITP 58 Endometrial Cancer 58 sargramostim 58 COPD exacerbation 58 mg q#h 58 Glatiramer Acetate 58 Posaconazole 58 REYATAZ R 58 subcutaneously administered 58 MDS MPD 58 Hematologic 58 erosive gastritis 58 phase IIb trial 58 discontinued Viread 58 tapentadol ER 58 liposomal formulation 58 baseline LDH 58 NS5B polymerase 58 recurrent VTE 58 PREZISTA r 58 Allovectin 7 58 Celsentri Selzentry 58 Hepatitis C Antiviral 58 Prostate AdenoCarcinoma Treatment 58 tobramycin inhalation solution 58 multigene expression test 58 #μg [002] 58 infliximab monotherapy 58 secondary endpoint 58 ongoing Phase 1b 58 plus Copegus R 58 NDA Submission 58 adefovir treated 58 primary patency 58 Adjuvant Chemotherapy 58 pharmacokinetic PK study 58 ug ml 58 DAS# [002] 58 Thrombocytopenia 58 demonstrated clinically meaningful 58 MabCampath 58 TAXUS Express Stent 58 Microalbuminuria 58 alemtuzumab treated 58 AIR CF1 58 placebo PBO 58 Neutropenia 58 CCR5 antagonist 58 urothelial carcinoma 58 adriamycin 58 carboplatin paclitaxel 58 FTC TDF 58 Phase III Clinical Trial 58 urate lowering therapy 58 Pegylated Liposomal Doxorubicin 58 Lantus ® 58 CYT# QbG# 58 HDAC Inhibitor 58 Localized Prostate Cancer 58 metastatic renal cell carcinoma 58 de novo kidney transplant 58 EURIDIS 58 dopamine partial agonist 58 deep venous thromboses 58 TDF FTC 58 scores TNSS 58 tipranavir 58 Initiated Phase 58 dual endothelin receptor antagonist 58 IIa Clinical Trial 58 Advanced Renal Cell 58 dose ritonavir 58 UPLYSO 58 intravenous bolus 58 Antiviral Therapy 58 hours postdose 58 EDEMA3 58 brand ciclesonide HFA 58 phase IIb study 58 Pulmonary Arterial Hypertension 58 lactate dehydrogenase LDH 57 cTnI 57 Score TOS 57 #.#mg/kg [002] 57 subanalysis 57 ibandronate 57 ALVESCO 57 Telithromycin 57 briakinumab 57 steroid refractory GvHD 57 Virus Infection 57 prolonged QT interval 57 Amgen Neulasta R 57 Myelofibrosis 57 minimally symptomatic 57 recurrent venous thromboembolism 57 anaphylactic reactions bronchospasm 57 Relapsed Refractory 57 mcg doses 57 QD dosing 57 erlotinib Tarceva ® 57 Serious adverse reactions 57 oral prodrug 57 RoACTEMRA

Back to home page